WO2010018731A3 - A mammalian rna dependent rna polymerase - Google Patents

A mammalian rna dependent rna polymerase Download PDF

Info

Publication number
WO2010018731A3
WO2010018731A3 PCT/JP2009/062840 JP2009062840W WO2010018731A3 WO 2010018731 A3 WO2010018731 A3 WO 2010018731A3 JP 2009062840 W JP2009062840 W JP 2009062840W WO 2010018731 A3 WO2010018731 A3 WO 2010018731A3
Authority
WO
WIPO (PCT)
Prior art keywords
rna
tert
compositions
mammalian
complex
Prior art date
Application number
PCT/JP2009/062840
Other languages
French (fr)
Other versions
WO2010018731A2 (en
Inventor
William Hahn
Kenkichi Masutomi
Yoshiko Maida
Yoshihide Hayashizaki
Timo Lassmann
Original Assignee
Japan Health Sciences Foundation
Riken
Dana-Farber Cancer Institute, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Health Sciences Foundation, Riken, Dana-Farber Cancer Institute, Inc. filed Critical Japan Health Sciences Foundation
Priority to US13/058,970 priority Critical patent/US20110243910A1/en
Publication of WO2010018731A2 publication Critical patent/WO2010018731A2/en
Publication of WO2010018731A3 publication Critical patent/WO2010018731A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/127—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07048—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

The invention provides compositions comprising a TERT-RMRP or TERT-RNA complex and methods of treating subjects with genetic diseases in which gene silencing is either increased by administering the compositions of the invention or decreased by administering an inhibitor of the RNA-dependent RNA polymerase (RdRP) activity of these compositions. Moreover, the invention provides methods of screening for agonists and antagonists of RdRP activity and TERT-RMRP complex formation. Finally, the invention provides a method of identifying a RNA molecule that forms a complex with a TERT polypeptide and has RdRP activity.
PCT/JP2009/062840 2008-08-12 2009-07-07 A mammalian rna dependent rna polymerase WO2010018731A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/058,970 US20110243910A1 (en) 2008-08-12 2009-07-07 mammalian rna dependent rna polymerase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18874308P 2008-08-12 2008-08-12
US61/188,743 2008-08-12

Publications (2)

Publication Number Publication Date
WO2010018731A2 WO2010018731A2 (en) 2010-02-18
WO2010018731A3 true WO2010018731A3 (en) 2010-07-15

Family

ID=41319635

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2009/062840 WO2010018731A2 (en) 2008-08-12 2009-07-07 A mammalian rna dependent rna polymerase

Country Status (2)

Country Link
US (1) US20110243910A1 (en)
WO (1) WO2010018731A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS59462B1 (en) 2010-02-16 2019-11-29 Ultimovacs As Polypeptides
KR20160102069A (en) * 2013-12-27 2016-08-26 텔로리젠, 인크. Compositions and methods for providing active telomerase to cells in vivo
EP3848056B1 (en) * 2014-08-08 2024-02-14 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Telomerase reverse transcriptase-based therapies
US20190083522A1 (en) * 2016-03-10 2019-03-21 President And Fellows Of Harvard College Biosynthetic modules
EP3426598B1 (en) 2016-03-11 2021-07-28 Children's Medical Center Corporation Nucleic acid nanoswitch catenanes
EP3494124B1 (en) 2016-08-02 2022-03-09 President and Fellows of Harvard College Crisscross cooperative self-assembly
CN114073760B (en) * 2020-08-21 2024-02-13 北京大学 Application of RDR protein in tumor treatment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000043501A2 (en) * 1999-01-22 2000-07-27 Humboldt-Universität Zu Berlin Universitätsklinikum Charite Ribozymes directed against the catalytic subunit of the human telomerase (htert)
WO2002072787A2 (en) * 2001-03-13 2002-09-19 Sierra Sciences, Inc. Telomerase expression repressor proteins and methods of using the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000043501A2 (en) * 1999-01-22 2000-07-27 Humboldt-Universität Zu Berlin Universitätsklinikum Charite Ribozymes directed against the catalytic subunit of the human telomerase (htert)
WO2002072787A2 (en) * 2001-03-13 2002-09-19 Sierra Sciences, Inc. Telomerase expression repressor proteins and methods of using the same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MAIDA YOSHIKO ET AL: "An RNA-dependent RNA polymerase formed by TERT and the RMRP RNA", NATURE (LONDON), vol. 461, no. 7261, 23 August 2009 (2009-08-23), pages 230, XP002564403, ISSN: 0028-0836 *
PETER T. ROWLEY ET AL: "Short interfering RNAs reduce telomerase activity in human cancer cells", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 44, no. 2, 7 February 2000 (2000-02-07), pages 1035, XP001537321 *

Also Published As

Publication number Publication date
WO2010018731A2 (en) 2010-02-18
US20110243910A1 (en) 2011-10-06

Similar Documents

Publication Publication Date Title
WO2010018731A3 (en) A mammalian rna dependent rna polymerase
Li et al. Let-7 microRNAs regenerate peripheral nerve regeneration by targeting nerve growth factor
Ota et al. ADAR1 forms a complex with Dicer to promote microRNA processing and RNA-induced gene silencing
Krishna et al. tRNA-derived fragments (tRFs): establishing their turf in post-transcriptional gene regulation
Jafarnejad et al. Translational control of ERK signaling through miRNA/4EHP-directed silencing
AU2003294440A1 (en) Methods for using riboprimers for strand displacement replication of target sequences
WO2007087451A3 (en) Compositions and methods for enhancing discriminatory rna interference
WO2007140958A3 (en) Method for identifying whether a patient will be responder or not to immunotherapy
SG170819A1 (en) Methods for the production of functional protein from dna having a nonsense mutation and the treatment of disorders associated therewith
EP1948674A4 (en) Modified sirna molecules and uses thereof
MX2009013646A (en) Methods of diagnosing and treating cancer.
NZ593228A (en) Gene expression markers (inhba) for colorectal cancer prognosis
WO2007038670A3 (en) Methods and compositions for screening and treatment of disorders of blood glucose regulation
WO2007034221A3 (en) Non small cell lung cancer therapy prognosis and target
EP2071025A4 (en) Primer set for amplification of ugt1a1 gene, reagent for amplification of ugt1a1 gene comprising the same, and use of the same
MX2009008508A (en) Compositions and methods to prevent cancer with cupredoxins.
WO2008073177A3 (en) Expression profiles associated with irinotecan treatment
DE112005001317A5 (en) Polymorphisms in the NOD2 / Card15 gene
WO2006044663A3 (en) THIO-siRNA APTAMERS
WO2005032495A3 (en) Gene expression profiles and methods of use
WO2008087641A3 (en) H19 silencing nucleic acid agents for treating rheumatoid arthritis
WO2009037266A3 (en) Method for detecting or quantifying a truncating mutation
MX2021007001A (en) Double-stranded nucleic acid inhibitor molecules containing a triloop.
MX2020010802A (en) DOUBLE-STRANDED NUCLEIC ACID INHIBITOR MOLECULES MODIFIED WITH T<sub>M</sub>-INCREASING NUCLEOTIDES.
Tolkachov et al. Loss of the hematopoietic stem cell factor GATA2 in the osteogenic lineage impairs trabecularization and mechanical strength of bone

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09787987

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13058970

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 09787987

Country of ref document: EP

Kind code of ref document: A2